TEZSPIRE
TEZSPIRE (Tezepelumab-ekko) is an FDA-approved monoclonal antibody therapy indicated for the treatment of severe asthma in adult and adolescent patients (12 years and older). Each 1×1.91 mL prefilled syringe contains Tezepelumab-ekko, designed for subcutaneous administration under professional supervision.
Tezepelumab works by blocking thymic stromal lymphopoietin (TSLP), a key epithelial cytokine involved in the inflammatory cascade of asthma. By targeting TSLP, TEZSPIRE helps reduce asthma exacerbations, improve lung function, and enhance overall symptom control, providing patients with a targeted treatment option for severe, uncontrolled asthma.
InfusionMed USA, based in Carrollton, Texas, supplies TEZSPIRE and other specialty pulmonary and immunology therapies to hospitals, clinics, and specialty infusion centers throughout Dallas, McKinney, Frisco, Plano, Lewisville, The Colony, and surrounding North Texas areas. We ensure cold-chain compliance, proper handling, and timely delivery for healthcare providers.
For professional use only.
Download Form